Comparison of persistence and adherence between fixed-dose combinations and two-pill combinations in Japanese patients with type 2 diabetes

References

• Seino Y, Kuwata H, Yabe D. Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig 2016;7(0):102-9
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation, 2017
   Google Scholar
• Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
   PubMed Web of Science ®Google Scholar
• Charvat H, Goto A, Goto M, et al. Impact of population aging on trends in diabetes prevalence: a meta-regression analysis of 160,000 Japanese adults. J Diabetes Investig 2015;6:533-42
   PubMed Web of Science ®Google Scholar
• Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspectives. Nat Rev Endocrinol 2011;8:228-36
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7
   PubMed Web of Science ®Google Scholar
• Neville SE, Boye KS, Montgomery WS, et al. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009;25:705-16
   PubMed Web of Science ®Google Scholar
• Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-94
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Wintfeld N, Huang J, et al. The association between nonadherence and glycated hemoglobin among type 2 diabetes patients using basal insulin analogs. Patient Prefer Adherence 2014;8:873-82
   PubMed Web of Science ®Google Scholar
• Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012;35:1279-84
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Rozenfeld Y, Hunt JS, Plauschinat C, et al. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008;14:71-5
   PubMed Web of Science ®Google Scholar
• Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74-109
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Promoting health and reducing disparities in populations. Diabetes Care 2017;40(Suppl 1):S6-S10
   PubMedGoogle Scholar
• Nagai Y. [Fixed-dose combination]. In Japanese. Nihon Rinsho 2015;73:465-9
   PubMedGoogle Scholar
• Fujibayashi K, Hayashi M, Yokokawa H, et al. Changes in antidiabetic prescription patterns and indicators of diabetic control among 200,000 patients over 13 years at a single institution in Japan. Diabetol Metab Syndr 2016;8:72
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The bias due to incomplete matching. Biometrics 1985;41:103-16
   PubMed Web of Science ®Google Scholar
• Council for International Organizations of Medical Sciences (CIOMS) in collaboration with the World Health Organization (WHO). International Ethical Guidelines for Epidemiological Studies. Geneva: CIOMS, 2009
   Google Scholar
• Public Policy Committee International Society of Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practice (GPP). Pharmacoepidemiol Drug Saf 2016;25:2-10
   Google Scholar
• Aoki K, Nagakura M, Taguri M, et al. Effect of switching from an anti-diabetic loose dose combination to a fixed dose combination regimen at equivalent dosage for 6 months on glycemic control in Japanese patients with type 2 diabetes: a pilot study. J Clin Med Res 2017;9:719-24
   PubMedGoogle Scholar
• Inagaki N, Onouchi H, Maezawa H, et al. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 2015;3:191-7
   PubMed Web of Science ®Google Scholar
• Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2015;16:2539-47
   PubMed Web of Science ®Google Scholar
• de Vries McClintock HF, Morales KH, Small DS, et al. A brief adherence intervention that improved glycemic control: mediation by patterns of adherence. J Behav Med 2015;38:39-47
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care 2018;41(Suppl 1):S1-S2
   PubMed Web of Science ®Google Scholar
• van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat 2014;2014:967073
   PubMedGoogle Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Indu R, Adhikari A, Maisnam I, et al. Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: an observational and questionnaire-based study. Perspect Clin Res 2018;9:139-44
   PubMedGoogle Scholar